Rationale Given that impairment of fear extinction plays a pivotal role in the pathophysiology of posttraumatic stress disorder (PTSD), drugs that facilitate fear extinction may be useful as novel treatments for PTSD. Histone deacetylase (HDAC) inhibitors have recently been shown to enhance fear extinction in animal studies. Objectives Using a single prolonged stress (SPS) paradigm, an animal model of PTSD, we examined whether the HDAC inhibitor vorinostat can facilitate fear extinction in rats, and elucidated the mechanism by which vorinostat enhanced fear extinction, focusing on the N-methyl-D-aspartate (NMDA) receptor signals in the hippocampus. Methods Seven days after SPS, rats received contextual fear conditioning, followed by 2-day extinction training. Vorinostat was intraperitoneally injected immediately after second extinction training session. Contextual fear response was assessed 24 h after vorinostat injection. Hippocampal tissues were dissected 2 h after vorinostat injection. The levels of mRNA and protein tested were measured by RT-PCR or western blotting, respectively. Results Systemic administration of vorinostat with extinction training significantly enhanced fear extinction in SPS rats as compared with the controls. Furthermore, vorinostat enhanced the hippocampal levels of NR2B and calcium/calmodulin kinase II (CaMKII) α and β proteins, accompanied by increases in the levels of acetylated histone H3 and H4. Conclusions These findings suggest that vorinostat ameliorated the impaired fear extinction in SPS rats, and this effect was associated with an increase in histone acetylation and thereby enhancement of NR2B and CaMKII in the hippocampus. Our results may provide new insight into the molecular and therapeutic mechanisms of PTSD.
Introduction
Posttraumatic stress disorder (PTSD) is a complex disorder associated with an intricate biological and psychological symptom profile and various common comorbidities. Despite the availability of various treatment strategies, PTSD is often resistant to treatment. Several randomized controlled studies have demonstrated the efficacy of cognitive behavioral therapy for the treatment of PTSD (Powers et al. 2010 ). Long-term treatments with selective serotonin reuptake inhibitors (SSRIs), such as sertraline and paroxetine, have shown efficacy in reducing symptom severity and relapse prevention (Strawn et al. 2010) . However, the therapeutic responses to these treatments vary and some PTSD patients fail to show an adequate response. Patients with PTSD often exhibit long-lasting reexperience of traumatic events, avoidance of the trauma-related stimuli, and hyperarousal, even though they recognize that the traumatic events are no longer occurring (Friedman et al. 1995) . However, the exact pathophysiology of PTSD remains unknown. Recent studies showed that extinction of learned fear may be impaired in PTSD patients (Blechert et al. 2007; Milad et al. 2009 ), suggesting that the impairment of fear extinction plays an important role in the development of clinical symptoms in PTSD (Milad et al. 2006; Rauch et al. 2006; Rothbaum and Davis 2003) .
Given that exposure therapy relies on an extinction-based mechanism, enhancing fear extinction through cognitive enhancers may represent a novel strategy for the treatment of PTSD. Several cognitive enhancers that alter GABAergic, glutamatergic, dopaminergic, noradrenergic, and cannabinoid pathways have been investigated in animal models of fear extinction (Kaplan and Moore 2011) . Among the agents classified as cognitive enhancers, D-cycloserine (DCS), a glutamatergic N-methyl-D-aspartate (NMDA) receptor partial agonist, has been extensively studied. Since the first such report by Walker and colleagues, many studies in animals and humans have demonstrated the facilitation of fear extinction by DCS (Davis et al. 2006; Ledgerwood et al. 2005; Walker et al. 2002) . However, recent clinical studies have shown that DCS fails to provide a significant therapeutic response in PTSD patients (Litz et al. 2012) , and further studies are needed to assess the efficacy of DCS for the treatment of PTSD.
Attention has been focused recently on histone deacetylase (HDAC) inhibitors as novel cognitive enhancers. HDAC inhibitors increase histone acetylation by blocking the activity of histone deacetylases, and these agents have recently been shown to enhance not only contextual fear conditioning (FC) but also fear extinction. For example, Lattal and associates showed that administration of HDAC inhibitors, such as sodium butyrate systemically or trichostatin A intrahippocampally, prior to a contextual extinction session produced greater effects than vehicle treatment in a context-evoked fear extinction model (Lattal et al. 2007 ). Bredy and colleagues reported that valproic acid enhanced fear extinction through histone H4 acetylation (Bredy et al. 2007) . Recently, we have demonstrated that the HDAC inhibitor vorinostat enhanced not only the original conditioned fear response but also extinction of the conditioned fear response, depending on the timing of drug administration. In the fear extinction paradigm, administration of vorinostat enhanced hippocampal levels of global acetylated histones as well as acetylated histones H3 and H4 at the promoter of the NR2B gene. In addition, the levels of NR2B mRNA and protein were increased, suggesting the involvement of vorinostat-mediated upregulation of NR2B in the process of enhanced fear extinction (Fujita et al. 2012) . Most recently, it has been demonstrated that the HDAC inhibitor MS-275 or valproic acid can rescue impaired extinction retrieval in a mouse model that exhibits impaired fear extinction (Whittle et al. 2013 ). However, beyond that, little is known about the effect of HDAC inhibitors on fear extinction in animal models of PTSD.
Vorinostat, an HDAC inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of refractory cutaneous T-cell lymphoma under the trade name Zolinza. Although vorinostat was primarily studied in the treatment of cancer, it has recently been applied in the preclinical development of a novel treatment regimen for memory disturbance. For example, chronic or acute injections of vorinostat into specific brain regions have been shown to increase synaptic plasticity and facilitate memory formation in mice (Guan et al. 2009; Peleg et al. 2010) . Vorinostat treatment of CBP+/-mice was correlated with elevated histone acetylation and improved memory function (Alarcon et al. 2004) . Furthermore, daily systemic administration of vorinostat for 19 days was found to rescue cognitive deficits in a mouse model of Alzheimer's disease (Kilgore et al. 2010) .
The aim of the present study was to clarify the effects of vorinostat on fear extinction using a single prolonged stress (SPS) paradigm, which has been validated as an animal model of PTSD (Yamamoto et al. 2009 ). Rats exposed to SPS mimic the pathophysiological abnormalities and behavioral characteristics of PTSD (Yamamoto et al. 2009 ), such as enhanced anxiety-like behavior (Imanaka et al. 2006 ) and enhanced glucocorticoid negative feedback (Liberzon et al. 1997) , and they exhibit the expected therapeutic response to long-term treatment with paroxetine on enhanced fear memory (Takahashi et al. 2006 ). In addition, SPS rats exhibit impaired extinction of fear memory such as enhanced contextual freezing (Iwamoto et al. 2007; Takahashi et al. 2006) , which is alleviated by DCS (Yamamoto et al. 2008) . In the present study, we first examined whether vorinostat with or without extinction training can enhance fear extinction in rats subjected to SPS, using a contextual FC paradigm. Second, we investigated the effect of vorinostat on the levels of acetylated histone H3 and H4 protein in the hippocampus. Finally, we examined the effect of vorinostat on NMDA-receptor signaling at the mRNA and protein levels in the hippocampus.
Materials and methods

Animals
Male Sprague-Dawley rats (8-weeks old) were purchased from Charles River Japan (Yokohama, Japan). The animals were group housed (three per cage) and maintained on a 12-h light/dark cycle with food and water freely available. All procedures took place during the light cycle. A different set of rats was used for each of the experiments. All animal procedures were conducted in strict accordance with the Hiroshima University School of Medicine Animal Care Committee Guiding Principles on Animal Experimentations in Research Facilities for Laboratory Animal Science, School of Medicine, Hiroshima University.
Single prolonged stress (SPS)
After a 1-week acclimatization period, rats were subjected to SPS. According to the method of associates (1997, 1999) , SPS was conducted in three stages: restraint for 2 h, forced swim for 20 min, and ether anesthesia. Each rat was restrained for 2 h by placing it inside a disposable clear polyethylene cone bag (Asahi Kasei, Tokyo, Japan) with only the tail protruding (Suenaga et al. 2004) . The large end of the cone was closed with tape at the base of the tail. The bag size was adjusted according to the size of the rat in order to achieve complete immobilization. A hole in the small end of the cone allowed the rats to breathe freely. After immobilization, the rats were individually placed in a clear acrylic cylinder (240 mm diameter, 500 mm height), filled two thirds from the bottom with water (24°C), and forced to swim for 20 min. Following 15-min recuperation, they were exposed to diethyl ether until loss of consciousness and then left undisturbed in their home cage for 7 days. As controls in Experiment 6, rats not subjected to SPS (sham rats) were left undisturbed in their home cage for 14 days.
Contextual FC and extinction training
Contextual FC was conducted 7 days after SPS. The experimental procedures for Experiment 1 are shown in Fig. 1a . Rats were placed in a conditioning chamber (325 W × 280H×500D mm) and then exposed to a 180-s conditioning context without any stimulation (e.g., a tone). Immediately afterward, they received a 4-s, 0.8 mA footshock through a stainless steel-grid floor by a shock generator-scrambler (SGS-003; Muromachi, Tokyo, Japan). Twenty-four hours after FC, rats were placed for 20 min without footshock in the conditioning chamber where they had previously received FC. Freezing was defined as the total absence of body or head movement except for that associated with breathing. Freezing behavior was recorded on videotape and later scored blindly by well-trained experimenters. Freezing was monitored using a time sampling method in which each rat was observed once every 5 s and a percentage score was calculated for the proportion of the total observation period spent frozen. Extinction training was defined as the repetitive exposure to the contextual cue (the apparatus) for 20 min in the absence of footshock. Extinction training was conducted on two consecutive days after FC. Freezing behavior was recorded for 5 min on the test day. As controls in Experiment 1, rats were not subjected to extinction training (Fig. 1b) .
Drug treatment
Vorinostat (Cayman Chemical, Ann Arbor, MI, USA) was dissolved in 250 μl of 100 % dimethyl sulfoxide (DMSO) and then injected (50 mg/kg per rat) intraperitoneally (Faraco et al. 2006; Kilgore et al. 2010) . Paroxetine (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 250 μl of 100 % DMSO and then injected (10 mg/kg per rat) intraperitoneally (Yamane 2001; Mathes et al. 2012 ). Control animals (SPS + DMSO) were administered an equal volume of 100 % DMSO. In Experiment 1, vorinostat was administered immediately after the second extinction training session (Fig. 1a) . Similarly, vorinostat was administered at the same time point in rats without extinction training (Fig. 1b) . In Experiment 5, paroxetine was administered immediately after the second extinction training session (Fig. 5a ).
Measurement of histone acetylation and NR2B protein levels and calcium/calmodulin kinase II (CaMKII) protein levels by western blotting According to our previous method, we selected the 2-h timepoint after vorinostat injection for the molecular studies (Fujita et al. 2012) . The procedures for the molecular experiments (Experiments 2, 3 and 4) are shown in Fig. 2a . Western blotting was performed to evaluate the effect of vorinostat on hippocampal histone H3 and H4 acetylation (Experiment 2), NR2B protein (Experiment 3), and CaMKII protein (Experiment 4) levels in the fear extinction studies. Rats were sacrificed by decapitation 2 h after drug injection. Similarly, western blotting was also undertaken to examine the effect of SPS on the levels of hippocampal histone H3 and H4 acetylation, NR2B protein, and CaMKII protein (Experiment 6; Fig. 7 ). Hippocampal lysates were prepared in homogenization buffer containing 50 mM Tris-HCl, pH 7.4, 1 mM ethylendiamine tetraacetic acid (EDTA), 150 mM NaCl, 1 % Triton X-100, 1 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 1 mM trichostatin A, phosphatase inhibitor cocktail (Sigma, St. Louis, MO, USA), and proteinase inhibitor cocktail (Complete, Roche Applied Science, Mannheim, Germany). Equal amounts of protein (20 μg) from each rat were fractionated on 4-12 % gradient Bis-Tris SDS NuPAGE gels (Invitrogen, Carlsbad, CA, USA) and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The blotted membranes were blocked with 0.1 % Tween 20/PBS (PBST) containing 5 % skim milk for detection of acetylated histone and CaMKII or 5 % BSA for other proteins, and incubated overnight at 4°C with antibodies diluted with PBST containing 2 % skim milk for acetylated histone and CaMKII or 2 % BSA for other proteins. The antibodies used included those specific for acetylated histone H3 (1:1000, Millipore, catalogue number 06-599, recognizing acetylated on lysine 14), acetylated histone H4 (1:500, Millipore, catalogue number 06-866, recognizing acetylated on lysine 5, 8, 12, and 16), histone H3 (1:4,000, Cell Signaling Technology, Beverly, MA, USA), histone H4 (1:2,000, Cell Signaling Technology), NR2B (1:400, BD Biosciences, San Jose, CA, USA), β-actin ( 1 : 4 0 , 0 0 0 , S i g m a , S t . L o u i s , M O , U S A ) , a n d CaMKII(1:2,500, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The membranes were then incubated with horseradish peroxidase (HRP)-conjugated antimouse IgG antibody (Jackson ImmunoResearch, West Grove, PA, USA) (antirabbit IgG antibody; [Jackson ImmunoResearch] for acetylated histone) in PBST containing 2 % skim milk or 2 % BSA for 1 h. The signals were visualized using ECL prime (GE Healthcare, Little Chalfont, Buckinghamshire, U.K.). The densities of the immunoreactive bands were quantified with ImageJ analysis software (version 1.44 for Windows; ImageJ, NIH, Bethesda, MD, USA). Data for acetylated histones and NR2B/CaMKII were corrected for the amount of total histone protein or β-actin protein in the sample, respectively.
Measurement of NMDA receptor levels in the hippocampus by RT-PCR
To elucidate the effect of vorinostat on hippocampal NMDA receptors, we measured alterations in NMDA-receptor mRNA levels (Experiment 3) using RT-PCR. Rats were sacrificed by decapitation 2 h after drug injection. Total RNA was extracted from the hippocampus with an RNAqueous Phenol-free Total RNA Isolation kit (Ambion, Austin, TX, USA). Single-stranded cDNA was synthesized using the QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany), which provided a procedure for genomic DNA elimination and reverse transcription. Levels of mRNA in the hippocampus were determined by RT-PCR using the ABI Prism 7900 sequence detection system (PE Applied Biosystems, Foster City, CA, USA). PCR was Fig. 1 a The experimental design in Experiment 1. Extinction training (ET) was conducted for 20 min per day on two consecutive days after fear conditioning (FC). Vorinostat was administered to rats with extinction training (extinction training group) immediately after the second extinction training session. b In rats without extinction training (no extinction training group), vorinostat was administered 48 h after FC, which corresponds to time point immediately after the second extinction training session. c The effect of vorinostat on fear extinction. Data are expressed as mean ± SEM (SPS + DMSO with ET; eight rats, SPS + vorinostat with ET; ten rats, SPS + DMSO without ET; eight rats, SPS + vorinostat without ET; ten rats). On day 3, freezing time in the SPS + vorinostat with extinction training group was reduced to a significantly greater extent than that in the SPS + DMSO with extinction training group. Freezing time in the SPS + DMSO with extinction training group was significantly reduced compared with that in the SPS + DMSO without extinction training group. Asterisk denotes significance at the 0.05 level carried out with TaqMan Universal PCR Master Mix (PE Applied Biosystems). All samples were assayed in triplicate. Thermal cycling was initiated with denaturation at 50°C for 2 min and 95°C for 10 min. After this initial step, 45 cycles of PCR (heating at 95°C for 15 s and 60°C for 1 min) were performed. The PCR assay for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was performed using the TaqMan Rodent GAPDH Control Reagents kit (PE Applied Biosystems). The ratio of the concentration of the target molecule to that of GAPDH (target molecule/GAPDH) in samples was calculated. The primers and probes were designed and synthesized as described previously (Table 1 ; Yamamoto et al. 2008 ).
Statistical analysis
All values shown represent the mean ± SEM. In Experiment 1, freezing responses of the four groups were compared by two-way ANOVA (SPS, extinction training), followed by appropriate post hoc comparisons to further analyze the group difference where necessary. Post hoc comparisons were performed using the Tukey-Kramer test. In other experiments, statistical analyses were performed using unpaired Student's t test. Results were considered statistically significant at p<0.05.
Results
Experiment 1: the effect of vorinostat and extinction training
In Experiment 1, two-way ANOVA revealed significant main effects associated with drug [F (1, 32) (Fig. 1c) . Post hoc analysis revealed that freezing time in SPS + vorinostat with extinction training group was reduced significantly more than that in the group that received SPS + DMSO with extinction training on day 3 (p< 0.05; Fig. 1c ). We also confirmed that there were no significant differences in freezing time between SPS + DMSO with extinction training and SPS + vorinostat with extinction training on days 1 and 2 ( Supplementary  Fig. 1b in Online Resource 1). These results suggest that vorinostat with extinction training enhances fear extinction in the SPS groups as well as in the sham groups ( Supplementary Fig. 1b in Online Resource 1) (Fujita et al. 2012) . As expected, the SPS + DMSO with extinction training group showed a significant decrease in freezing time compared with SPS + DMSO without extinction training group (Fig. 1c) , suggesting that extinction training itself enhances fear extinction to some extent. On the other hand, post hoc analysis revealed that there was no significant difference in freezing time between the SPS + DMSO without extinction training and SPS + vorinostat without extinction training groups (p<0.05; Fig. 1c ), suggesting that extinction training is necessary for the promotion of fear extinction by vorinostat.
Experiment 2: the effect of vorinostat on acetylated histone H3 and H4
In Experiment 2, the hippocampal levels of acetylated histone and total histone levels 2 h after administration of vorinostat were measured by western blotting. The levels of acetylated H3 and H4 in the SPS + vorinostat group were significantly Fig. 2 (Fig. 2b ).
Experiment 3: the effect of vorinostat on NMDA receptor gene expression and protein levels in the hippocampus.
In Experiment 3, the hippocampal mRNA levels of NMDA receptor subunits 2 h after administration of vorinostat were measured. The levels of NR2B mRNA in the SPS + vorinostat group were significantly higher than those in the SPS + DMSO group [t (18)=2.42, p< 0.05] (Fig. 3a) . There were no significant differences between the two groups in the levels of NR1 and NR2A mRNA [NR1, t (18)=0.37, p=0.72; NR2A, t (18)=0.65, p=0.53]. Since upregulation of expression was observed only for the NR2B gene, we selectively evaluated NR2B protein levels by western blotting and found that the NR2B protein levels in the SPS + vorinostat group were significantly higher than those in the SPS + DMSO group [t (18)=4.35, p<0.05] (Fig. 3b ). By contrast, vorinostat itself did not induce significant changes in the hippocampal levels of NR2B protein [SPS + DMSO without extinction training 1.00± 0.12, SPS + vorinostat without extinction training 0.84±0.16, t (10) =0.79, p=0.45] (Supplementary Fig. 3 in Online Resource 1).
Experiment 4: the effect of vorinostat on CaMKII protein levels in the hippocampus
In Experiment 4, the protein levels of CaMKIIα and CaMKIIβ in the hippocampus 2 h post-injection were measured by western blotting. The protein levels of CaMKIIα and CaMKIIβ in the SPS + vorinostat group were significantly increased compared with those in the SPS + DMSO group [CaMKIIα, t (18)=5.05, p<0.05; CaMKIIβ, t (18)= 3.55, p<0.05] (Fig. 4 ).
Experiment 5: the effect of paroxetine on fear extinction
Since the acute effect of paroxetine on fear extinction in combination with extinction training is unknown, in Experiment 5, we administrated paroxetine immediately after the second extinction training session to SPS rats and examined the effect of a single administration of paroxetine on freezing (Fig. 5a ). There was no significant difference in the freezing time between the SPS + DMSO and SPS + paroxetine groups [t (16)=1.16, p=0.27] (Fig. 5b) . Paroxetine also did not change hippocampal histone H3 and H4 acetylation, NR2B protein, and CaMKII protein levels (Supplementary Fig. 2 in Online Resource 1).
Experiment 6: measurement of the acetylated histone H3 and H4, NR2B, and CaMKII protein levels in the sham and SPS groups
In Experiment 6, we investigated the effect of SPS itself on hippocampal histone H3 and H4 acetylation, NR2B protein, and CaMKII protein levels. Rats in the two groups received neither FC nor drug treatment (Fig. 6 ). There were no significant differences in the protein levels of acetylated histone H3 and H4, NR2B, or CaMKII between the sham and SPS groups [H3, t (10)=1.12, p=0.30; H4, t (10)=0.97, p=0.36; NR2B, t (10)=1.48, p=0.17; CaMKIIα, t (10)= 0.78, p=0.45; CaMKIIβ, t (10)=0.47, p=0.65] (Fig. 7) .
Discussion
Recent studies have demonstrated that HDAC inhibitors can enhance fear extinction through histone acetylation (Bredy and Barad 2008; Lattal et al. 2007; Stafford et al. 2012) . Therefore, in the present study, we examined whether the HDAC inhibitor vorinostat can alleviate the impaired extinction of fear memory in rats subjected to SPS, and we explored the drug's mechanism of action. The key finding of the present study was that a single treatment with vorinostat, combined with extinction training, in SPS rats markedly enhanced fear extinction as compared with SPS rats treated with vehicle (DMSO). This effect of vorinostat was not found in SPS rats without extinction training. Furthermore, vorinostat led to an increase in hippocampal levels of NR2B Fig. 3 a The effect of vorinostat on NMDA receptor gene expression in the hippocampus. Data are expressed as the ratio of the concentration of the target molecule to that of GAPDH (target molecule/ GAPDH) and presented as the mean ± SEM of ten rats per group. The SPS + vorinostat group exhibited a significant increase in NR2B mRNA levels relative to the SPS + DMSO group. There were no significant differences in the levels of NR1 and NR2A mRNA between the two groups. b The effect of vorinostat on hippocampal NR2B protein levels. Data for NR2B protein are expressed as the ratio of the NR2B concentration to that of β-actin (NR2B/β-actin) and presented as the mean ± SEM of ten rats per group. The SPS + vorinostat group exhibited a significant increase in NR2B protein levels relative to the SPS + DMSO group. *p<0.05; unpaired Student's t test Fig. 4 The effect of vorinostat on hippocampal CaMKIIα and CaMKIIβ protein levels. Data are expressed as the ratio of the target molecule concentration to that of β-actin (target molecule/ β-actin) and presented as the mean ± SEM of ten rats per group. The SPS + vorinostat group exhibited a significant increase in CaMKIIα and CaMKIIβ protein levels relative to the SPS + DMSO group. *p<0.05; unpaired Student's t test and CaMKIIα/β, which was accompanied by rapid increases in the levels of acetylated histone H3 and H4; however, vorinostat itself or SPS manipulation did not affect the levels of NR2B and CaMKIIα/β or the levels of acetylated histone H3 and H4. To our knowledge, this is the first study investigating the extinction promoting effect of HDAC inhibitors in a rat model of PTSD.
To ensure the success of PTSD treatment, it is important to diminish the spontaneous or cue-induced reexperience of fear memory. We previously found that 5-day treatment with DCS combined with extinction training significantly enhanced fear extinction in SPS rats (Yamamoto et al. 2008) . Although the enhancement of fear extinction was already observed after 2-day treatment with DCS, the effect was weaker than that after 5-day treatment (Yamamoto et al. 2008) . Surprisingly, in the present study, we observed that one treatment with vorinostat on the second day of extinction training dramatically enhanced fear extinction on day 3 (Fig. 1) to an extent similar to that seen after 5-day treatment with DCS (Yamamoto et al. 2008) . Therefore, in terms of rapid therapeutic responses, it is conceivable that vorinostat may be superior to DCS.
Based on the findings in the present study, it is postulated that this rapid therapeutic action of vorinostat is due to alterations in gene expression through HDAC inhibition. Although we previously demonstrated that chronic administration of paroxetine, one of the first-line drugs in the treatment of PTSD, alleviated the fear response in SPS rats without extinction training (Takahashi et al. 2006) , it is unlikely that conventional drugs used in the treatment of PTSD have a similar effect. In this context, we examined the effect of single administration of paroxetine on freezing time in SPS rats using an identical experimental paradigm as that used for vorinostat. As expected, paroxetine had no effect on fear extinction or on the levels of acetylated H3 or H4, NR2B, or CaMKII. These results taken together with the results of the DCS study indicate that it is likely that HDAC inhibition plays an important role in the rapid therapeutic response of vorinostat.
In SPS rats, increased levels of acetylated histone H3 and H4 were observed after administration of vorinostat with extinction training. In addition, the levels were not affected by SPS itself. Furthermore, our previous study showed that there were no differences in the levels of acetylated histone Fig. 5 a The experimental design in Experiment 5. Extinction training (ET) was conducted for 20 min per day on two consecutive days after fear conditioning (FC). Paroxetine was administered to rats immediately after the second extinction training session. b The effect of paroxetine on fear extinction. Data are expressed as mean ± SEM of nine rats per group. On the test day (day 3), there was no significant difference in the freezing time between the two groups Fig. 6 The experimental design in Experiment 6. In the sham group, rats were undisturbed in their home cage for 14 days without SPS procedure, and then hippocampal tissues were collected. In the SPS group, hippocampal tissues were collected 7 days after SPS H3 and H4 before and 2 h after FC (Takei et al. 2010) . Based on these results, our findings suggest that increased levels of histone acetylation in response to vorinostat could result in improvement of the impaired fear extinction in SPS rats. As noted above, several studies have shown that HDAC inhibitors enhanced fear extinction through histone acetylation (Bredy and Barad 2008; Lattal et al. 2007; Stafford et al. 2012) . Likewise, our results support the effectiveness of HDAC inhibitors as shown in previous reports. Given that little is known about the pathophysiology of PTSD or the therapeutic mechanisms of drugs used in the treatment of PTSD (e.g., SSRIs), our results also provide novel mechanistic information. Interestingly, it is possible that the acetylation of non-histone proteins may participate in the mechanism of memory enhancement, in addition to the acetylation of histone proteins. It has been reported that many HDACs deacetylate non-histone proteins such as α-tubulin, p53, NF-κB, and various transcription factors (Buchwald et al. 2009 ). In particular, the NF-κB pathway plays an important role in memory enhancement in response to HDAC inhibitors (Yeh et al. 2004) ; thus, this pathway also may contribute to the enhancement of fear extinction.
Concerning the molecular mechanisms of fear memory extinction, NMDA-receptor signaling is of great interest in part because of recent findings with DCS, an NMDAreceptor partial agonist (Myers and Carlezon 2012; Davis 2011) . A meta-analysis revealed that DCS enhanced fear extinction/exposure therapy in both animals and humans with anxiety disorder (Norberg et al. 2008) , which is consistent with our previous study demonstrating that DCS alleviated the impaired fear extinction in SPS rats (Yamamoto et al. 2008) . Therefore, NMDA-receptor signaling may be, at least in part, involved in the alleviation of impaired fear extinction in SPS rats. Among the NMDA-receptor subunits, NR2B plays a pivotal role in fear extinction. In a study by Tang and associates, facilitation of fear extinction was observed in mice in which the expression of NR2B in the forebrain was genetically upregulated (Tang et al. 1999) . In a recent study of naïve rats subjected to contextual FC, we showed that vorinostat markedly increased the hippocampal levels of acetylated histone H3 and H4 at the promoter of the NR2B gene, which was followed by increased levels of NR2B mRNA and proteins, and subsequently, enhancement of fear extinction (Fujita et al. 2012) . Fig. 7 a The effect of SPS on the levels of acetylated histone H3 and H4. Data are expressed as the ratio of the acetylated histone concentration to that of total histone protein (acetylated histone/total histone) and presented as the mean ± SEM of six rats per group. There were no significant differences in the levels of acetylated histone H3 and H4 between the two groups. b The effect of SPS on the levels of NR2B. Data are expressed as the ratio of NR2B concentration to that of β-actin (NR2B/β-actin) and presented as the mean ± SEM of six rats per group. There was no significant difference in the level of NR2B protein between the two groups. c The effect of SPS on the levels of CaMKIIα and CaMKIIβ. Data are expressed as the ratio of the target molecule concentration to that of β-actin (target molecule/ β-actin) and presented as the mean ± SEM of six rats per group. There were no significant differences in the levels of CaMKIIα and CaMKIIβ protein between the two groups. Ac = acetylated
In the present study, we found vorinostat-induced NR2B up-regulation in SPS rats as well as in naïve rats, in parallel with the improvement of impaired fear extinction by vorinostat. As mentioned above, vorinostat was found to enhance histone acetylation at the promoter of the NR2B gene, as measured using a ChIP-assay (Fujita et al. 2012 ). Although we did not examine whether vorinostat increased the levels of acetylated histone at the promoter of the NR2B gene in SPS rats, our results suggest that direct upregulation of the transcription of the NR2B gene in response to vorinostat may alleviate the impairment of fear extinction in SPS rats. We also found that vorinostat rapidly increased CaMKIIα/β levels in SPS rats, while the levels were unaffected by SPS alone. It is well known that CaMKII and NMDA receptors cooperate functionally. For example, the induction of NMDA receptor-mediated hippocampal longterm potentiation requires the activity of CaMKII (Nicoll and Malenka 1995; Sanhueza et al. 2011) . It has also been revealed that CAMKII interacts with NR2B (Robison et al. 2005; Bayer et al. 2006) . Furthermore, a report by Szapiro and colleagues showed that CaMKII plays a role in fear extinction (Szapiro et al. 2003 ). Thus, it is possible that such functional cooperation of NR2B with CAMKIIα/β may contribute to vorinostat-mediated enhancement of fear extinction.
There are some limitations of the current study. First, we cannot rule out the possibility that vorinostat affected the expression of other genes associated with learning and memory, in addition to NR2B and CaMKIIα/β. To address this issue, it will be necessary to conduct a genome-wide screening approach using ChIP-sequencing in animal models of PTSD. Secondly, it is well established that brain regions other than the hippocampus, such as the amygdala and prefrontal cortex, contribute to fear extinction; thus, the contribution of these regions to the therapeutic effect of vorinostat should be investigated. Lastly, although our study implicates the hippocampal NMDA-CaMKII pathway as a key factor in the enhancement of fear extinction by vorinostat, other downstream molecules and/or pathways may also play a role. This possible mechanism of action of vorinostat awaits further investigation.
In summary, the results of the present study demonstrate that vorinostat ameliorates the impaired fear extinction in SPS rats by increasing the expression of NR2B and CaMKII in the hippocampus, which is accompanied by increased acetylation of histone H3 and H4. These findings suggest that vorinostat in combination with exposure therapy can be a promising pharmacological tool for the treatment of PTSD. Thus, it is necessary to further investigate the effects of vorinostat treatment in PTSD patients. There are, however, certain limitations that should be kept in mind regarding the clinical use of vorinostat. For instance, currently available HDAC inhibitors are not targeted toward specific genes, so adverse effects can occur with chronic treatment, as is the case in cancer therapy. In this regard, our study suggests that a single treatment with vorinostat combined with exposure therapy might produce positive treatment responses with an acceptable safety profile. It remains unclear whether or not epigenetic dysregulation exists in PTSD. It is desirable to identify such epigenetic dysregulation in PTSD in order to facilitate the development of epigenetic drugs that may be more specific for PTSD. In addition, such efforts could eventually lead to a better understanding of the pathophysiology of PTSD. Conflict of interest All authors declare that they have no conflicts of interest.
